MarginsXMarginsX
Home › Markets › Health Care › IQV

IQVIA Holdings Inc. (IQV)

IQV trades on NYSE in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$264.73
-0.15% on the day
Market cap
$43.6B
Large cap
Revenue · 2025
$16.3B
+5.9% on 2024
Net income · 2025
$1.4B
8.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/0001628280-26-008322-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIQV on NYSE
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2013
SEC CIK0001478242
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$16.3B
Net income$1.4B
Operating income$2.2B
Net margin8.3%
Operating margin13.4%
Revenue growth+5.9%
Cash$2.0B
Total assets$29.9B
P/E (computed)32.1×
P/S (computed)2.7×

Warning signs

Cash runway
Cash-flow positive
$2.2B cash at September 30, 2026
Share count, 1 year
-3.2%
2025-10-20 to 2026-10-20 · -9.7% over 3 years
Going-concern doubt
No
10-Q filed October 27, 2026
Insider net buying, 12 months
-$51.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-27
Cash and burn$2.2B cash; operating cash flow $684.0M a quarter.Report 2026-09-30
Shares outstanding164,800,000 (2026-10-20); 170,300,000 a year earlier; 182,500,000 three years earlier.Cover page 2026-10-20
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Raleigh, North Carolina, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $51.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$4.4B$350.0M$825.0M$2.2B$16.1B$17.3B10-Q 2026-10-27
Q2 2026
2026-06-30
$4.4B$256.0M$558.0M$1.9B$16.0B$17.0B10-Q 2026-07-28
Q1 2026
2026-03-31
$4.2B$274.0M$618.0M$1.9B$15.8B$16.6B10-Q 2026-05-05
Q4 2025
2025-12-31
$4.4B$514.0M$735.0M$2.0B$15.7B$16.3B10-K 2026-02-17
Q3 2025
2025-09-30
$4.1B$331.0M$908.0M$1.8B$15.0B$15.9B10-Q 2026-10-27
Q2 2025
2025-06-30
$4.0B$266.0M$443.0M$2.0B$15.5B$15.7B10-Q 2026-07-28
Q1 2025
2025-03-31
$3.8B$249.0M$568.0M$1.7B$14.3B$15.5B10-Q 2026-05-05
Q4 2024
2024-12-31
$4.0B$437.0M$885.0M$1.7B$14.0B$15.4B10-K 2026-02-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32024-01-25
Latest annual report10-K2026-02-17
Latest quarterly / interim10-Q2026-10-27
Latest current report8-K2026-10-27
Latest proxyDEFA14A2026-02-27

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.5%
1 month+1.7%
3 months+9.8%
Year to date+17.6%
1 year+18.6%
From 52-week high-5.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
INCYIncyte Corp.$120.27-0.58%$24.5B
MEDPMedpace Holdings Inc.$648.20-0.88%$18.1B
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B
ICLRICON plc$191.40-1.67%$14.7B
ABSIAbsci Corporation$7.47-11.54%$1.3B
OABIOmniAb Inc.$4.89-0.41%$713.3M
NRCNRC Health$26.33-0.87%$558.8M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier